col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Publishing House: American Society for Pharmacology & Experimental Therapeutics

26 Results       Page 1

 [1] 
  original article Journal Date Title Authors All Authors
1 [GO] Drug Metabolism and Disposition 2024―Oct―29 Uncovering the Impact of COVID-19 Mediated Bidirectional Dysregulation of CYP3A4 on Systemic and Pulmonary Drug Concentrations Using Physiologically Based Pharmacokinetic Modeling Chukwunonso K. Nwabufo
2 [GO] Journal of Pharmacology and Experimental Therapeutics 2024―Aug―23 KVX-053, a Protein Tyrosine Phosphatase 4A3 inhibitor, ameliorates SARS-CoV-2 Spike protein subunit 1 - induced acute lung injury in mice Pavel A Solopov, Ruben Manuel Luciano Colunga Biancatelli, Tierney Day, Betsy Gregory, Elizabeth R Sharlow, John S. Lazo, John D Catravas
3 [GO] Journal of Pharmacology and Experimental Therapeutics 2024―Feb―09 Endothelial extracellular vesicles enriched in microRNA-34a predict new-onset diabetes in COVID-19 patients: novel insights for long-COVID metabolic sequelae Pasquale Mone, Stanislovas S. Jankauskas, Maria Virginia Manzi, Jessica Gambardella, Antonietta Coppola, Urna Kansakar, et al. (+7)
4 [GO] Molecular Pharmacology 2023―Oct―12 Targeting Cyclophilin A and CD147 to Inhibit Replication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and SARS-CoV-2-Induced Inflammation Fan Yang, Chenglong Liu, Pengyuan Li, Aihua Wu, Yue Ma-Lauer, Hao Zhang, et al. (+4)
5 [GO] Drug Metabolism and Disposition 2023―Sep―14 The Metabolism of Lufotrelvir, a Prodrug Investigated for the Treatment of SARS-COV2 in Humans Following Intravenous Administration Narayan Cheruvu, Esther van Duijn, Pieter A. Spigt, Ioana M. Barbu, Sima S. Toussi, Klaas Schildknegt, et al. (+2)
6 [GO] Journal of Pharmacology and Experimental Therapeutics 2023―Apr―27 Modulation of the immune response to SARS-CoV-2 vaccination by NSAIDs Carsten Skarke, Ronan Lordan, Kayla Barekat, Amruta Naik, Divij Mathew, Takuya Ohtani, et al. (+13)
7 [GO] Drug Metabolism and Disposition 2022―Oct―31 COVID-19 Vaccines and the Virus: Impact on Drug Metabolism and Pharmacokinetics Eliza R McColl, Maria A. Croyle, William C. Zamboni, William G Honer, Mark Heise, Micheline Piquette-Miller, Kerry B. Goralski
8 [GO] Drug Metabolism and Disposition 2022―Aug―30 The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro Yue Shen, William Eades, William Liu, Bingfang Yan
9 [GO] Journal of Pharmacology and Experimental Therapeutics 2022―Jul―03 Cardiovascular implications of miRNAs in COVID-19 Carmine Izzo, Valeria Visco, Jessica Gambardella, Germano Junior Ferruzzi, Antonella Rispoli, Maria Rosaria Rusciano, et al. (+7)
10 [GO] Journal of Pharmacology and Experimental Therapeutics 2022―Jun―30 Exosomal miR-145 and miR-885 regulate thrombosis in COVID-19 Jessica Gambardella, Urna Kansakar, Celestino Sardu, Vincenzo Messina, Stanislovas S. Jankauskas, Raffaele Marfella, et al. (+6)
11 [GO] Journal of Pharmacology and Experimental Therapeutics 2022―Mar―26 L-Arginine Enhances the Effects of Cardiac Rehabilitation on Physical Performance: New Insights for Managing Cardiovascular Patients During the COVID-19 Pandemic Pasquale Mone, Raffaele Izzo, Giuseppe Marazzi, Maria Virginia Manzi, Paola Gallo, Giuseppe Campolongo, et al. (+6)
12 [GO] Drug Metabolism and Disposition 2022―Feb―13 Disposition of PF-07321332 (Nirmatrelvir), an Orally Bioavailable Inhibitor of SARS-CoV-2 3CL Protease, across Animals and Humans Heather Eng, Alyssa L Dantonio, Eugene P Kadar, R. Scott Obach, Li Di, Jian Lin, et al. (+7)
13 [GO] Molecular Pharmacology 2022―Feb―01 A Comment on “Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites” Eric K. Johnson
14 [GO] Molecular Pharmacology 2022―Feb―01 Response to Comments on “Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites” Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright, Nathan J. Cherrington
15 [GO] Pharmacological Reviews 2022―Jan―31 Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli, Qiang Ma
16 [GO] Molecular Pharmacology 2021―Sep―09 Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright, Nathan J. CHERRINGTON
17 [GO] Journal of Pharmacology and Experimental Therapeutics 2021―Jul―12 Cationic Compounds with SARS-CoV-2 Antiviral Activity and their Interaction with OCT/MATE Secretory Transporters. Lucy Jazmin Martinez Guerrero, Xiaohong Zhang, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright
18 [GO] Journal of Pharmacology and Experimental Therapeutics 2021―May―10 Viral Proteases as Targets for COVID-19 Drug Development Wei Zhu, Zeenat A Shyr, Donald C. Lo, Wei Zheng
19 [GO] Pharmacological Reviews 2021―Mar―09 Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics Peter Garred, Andrea J. Tenner, Tom E. Mollnes, Finn Olav Levy
20 [GO] Journal of Pharmacology and Experimental Therapeutics 2021―Mar―05 COVID-19 drugs chloroquine and hydroxychloroquine, but not azithromycin and remdesivir, block hERG potassium channels Mark Szendrey, Jun Guo, Wentao Li, Tonghua Yang, Shetuan Zhang
21 [GO] Journal of Pharmacology and Experimental Therapeutics 2020―Oct―28 A Biomarker-Centric Approach to Drug Discovery and Development: Lessons Learned from the COVID-19 Pandemic Kelly A. Fader, Jiangwei Zhang, Joseph P. Menetski, Ravi I. Thadhani, Elliott M. Antman, Gary S. Friedman, et al. (+2)
22 [GO] Molecular Pharmacology 2020―Oct―21 Dysregulation of ACE2 Expression and Function in Co-morbid Disease Conditions Possibly Contributes to COVID-19 Complication Severity Safaa Hammoud, Zena Wehbe, Samar Abdelhady, Firas Kobeissy, Ali Hussein Eid, Ahmed F El-Yazbi
23 [GO] Journal of Pharmacology and Experimental Therapeutics 2020―Oct―08 The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19 Ali Ehsan Sifat, Saeideh Nozohouri, Heidi Villalba, Bhuvaneshwar Vaidya, Thomas J. Abbruscato
24 [GO] Journal of Pharmacology and Experimental Therapeutics 2020―Oct―02 Role of GILZ in the Kidney and the Cardiovascular System: Relevance to Cardiorenal Complications of COVID-19 Mahmood Mozaffari
25 [GO] Molecular Pharmacology 2020―Sep―10 Heparin-binding peptides as novel therapies to stop SARS-CoV-2 cellular entry and infection Omid Tavassoly, Farinaz Safavi, Iman Tavassoly
26 [GO] Journal of Pharmacology and Experimental Therapeutics 2020―Jul―29 Drug discovery strategies for SARS-CoV-2 Zeenat A Shyr, Kirill Gorshkov, Catherine Z Chen, Wei Zheng
 [1] 

26 Results       Page 1



[de][en]

Last change 2025―Jul―29 14:55:09 UTC

© Daten-Quadrat 2022       Done in 0.004 sec